EHA 2016 | The importance of blinatumomab and inotuzumab ozogamicin in treating ALL
Josep-Maria Ribera, MD, PhD from Germans Trias i Pujol University Hospital, Barcelona, Spain outlines the importance of blinatumomab and inotuzumab ozogamicin in treating acute lymphoblastic leukemia (ALL). Both blinatumomab and inotuzumab ozogamicin are very effective in a relapsed/refractory settings. Dr Ribera believes that these agents are best used earlier in the disease, specifically in first remission, when there is still minimal residual disease (MRD) to be eliminated. Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
Get great new content delivered to your inboxSign up